Merck & Co., one of the victims of the Petya cyberattack last month, has yet to fully restore its manufacturing and R&D operations since they were hit more than four weeks ago. The attack and its costs didn’t hit its
read moreSamsung and partner Merck have launched their Remicade biosimilar in the U.S., Mitsubishi Tanabe is buying CNS expert NeuroDerm for $1.1 billion, Takeda and Schrödinger formed a multiprogram drug discovery pact worth up to $170 million project and more. More:
read moreNovo Nordisk’s diabetes drug Victoza is now approved in Europe as the only GLP-1 analogue with a label including prevention of cardiovascular events. More: EU approves CV benefit claim for Novo’s Victoza Source: News
read moreCost regulators for NHS treatments in England and Wales are backing use of Allergan’s Truberzi to treat irritable bowel syndrome with diarrhoea (IBS-D) in patients who have not responded to or cannot take other treatments. More: NICE nod for Allergan’s
read moreCelgene has unveiled a meta-analysis of pooled data from three late-stage studies showing a significant overall survival benefit in patients newly diagnosed with multiple myeloma receiving Revlimid as maintenance therapy following autologous stem cell transplantation. More: Revlimid boosts survival in
read moreCancer Research UK has brought its commercialisation arm, Cancer Research Technology (CRT), together with its research funding teams to form a new in-house division called Research and Innovation. More: CRUK brings commercialisation arm in-house Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals